Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
Non Small Cell Lung Cancer · KRAS Activating Mutation · Advanced Cancer · Metastatic Cancer · Malignant Neoplasm of Lung · Malignant Neoplastic Disease
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +11.5
A key executive is leaving
Since Oct 14, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 12 (final count)
- Started
- Aug 1, 2022
- Main results expected
- Jun 15, 2026
- Fully finished
- Jun 15, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A: To determine RP2D for avutometinib(VS-6766) in combination with adagrasib
Measured over: From start of treatment to confirmation of RP2D; 28 days
To determine the efficacy of the optimal regimen identified from Part A
Measured over: From start of treatment to confirmation of response; 16 weeks
Changes Tremor has spotted
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 11.5, since 2026-10-14, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05375994 · record last updated 2026-07-02 · checked 2026-11-09 15:36 UTC